OUTSTANDING INTEREST PAPERS
General aspects of Allergen-Specific Immunotherapy:
Calderon MA, Larenas D, Kleine-Tebbe J, Jacobsen L, Passalacqua G, Eng PA, Varga EM, Valovirta E, Moreno C, Malling HJ, Alvarez-Cuesta E, Durham S, Demoly P. European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy'. Allergy. 2011 Jun 28. doi: 10.1111/j.1398-9995.2011.02669.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/21707645
Subcutaneous Immunotherapy:
Pfaar O, Urry Z, Robinson DS, Sager A, Richards D, Hawrylowicz CM, Bräutigam M, Klimek L. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy. 2011 Nov; doi: 10.1111/j.1398-9995.2011.02736.x. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed?term=A%20randomized%20placebo-controlled%20trial%20of%20rush%20preseasonal%20depigmented%20polymerized%20grass%20pollen%20immunotherapy
Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol. 2010 Mar;125(3):569-74.
http://www.ncbi.nlm.nih.gov/pubmed/20144472
Soyer OU, Akdis M, Akdis CA. Mechanisms of subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am. 2011 May;31(2):175-90, vii-vii.
http://www.ncbi.nlm.nih.gov/pubmed/21530813
Cox L, Nelson H, Lockey R et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55. Epub 2010 Dec 3
http://www.ncbi.nlm.nih.gov/pubmed?term=21122901
Sublingual Immunotherapy:
Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009 Dec;64 Suppl 91:1-59
http://www.ncbi.nlm.nih.gov/pubmed/20041860
Scadding G, Durham SR. Mechanisms of sublingual immunotherapy. Immunol Allergy Clin North Am. 2011 May;31(2):191-209, viii.
http://www.ncbi.nlm.nih.gov/pubmed/21530814
Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010 Jan;125(1):131-8.e1-7.
http://www.ncbi.nlm.nih.gov/pubmed/20109743
Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009 Sep;124(3):471-7.
http://www.ncbi.nlm.nih.gov/pubmed?term=19647862
Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010 Dec 8;(12).
http://www.ncbi.nlm.nih.gov/pubmed/21154351
Future approaches:
Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol. 2011 Jan;127(1):8-15;
http://www.ncbi.nlm.nih.gov/pubmed?term=21094518
Valenta R, Linhart B, Swoboda I, Niederberger V.Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy. 2011 Jun;66(6):775-83.
http://www.ncbi.nlm.nih.gov/pubmed?term=21352238
Moldaver D, Larche M. Immunotherapy with peptides. Allergy. 2011 Jun;66(6):784-91
http://www.ncbi.nlm.nih.gov/pubmed?term=21507007
Senti G, von Moos S, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy. 2011 Jun;66(6):798-809
http://www.ncbi.nlm.nih.gov/pubmed?term=21518374
Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009;150(1):59-65.
http://www.ncbi.nlm.nih.gov/pubmed/19339803
Suzuki K, Kaminuma O, Yang L, et al Development of transgenic rice expressing mite antigen for a new concept of immunotherapy. Int Arch Allergy Immunol. 2009;149 Suppl 1:21-4
http://www.ncbi.nlm.nih.gov/pubmed/19494500
Non respiratory allergens
Bilo BM, Bonifazi F. Hymenoptera venom immunotherapy. Immunotherapy. 2011 Feb;3(2):229-46.
http://www.ncbi.nlm.nih.gov/pubmed/21322761
Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy. 2009 Sep;64(9):1237-45.
http://www.ncbi.nlm.nih.gov/pubmed/19627278
Nowak-Wegrzyn A, Sampson HA. Future therapies for food allergies. J Allergy Clin Immunol. 2011 Mar;127(3):558-73.
http://www.ncbi.nlm.nih.gov/pubmed/21277625
Fernandez-Rivas M, Garrido Fernandez S, Nadal JA et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009 Jun;64(6):876-83.
http://www.ncbi.nlm.nih.gov/pubmed/19183164
Other:
Bousquet J, Schunemann HJ, Bousquet PJ et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy. 2011 Jun;66(6):765-74.
http://www.ncbi.nlm.nih.gov/pubmed?term=21496059
Ring J, Gutermuth J.100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). Allergy. 2011 Jun;66(6):713-24
http://www.ncbi.nlm.nih.gov/pubmed?term=21320133
Bousquet PJ, Calderon MA, Demoly P, et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol. 2011 Jan;127(1):49-56.
http://www.ncbi.nlm.nih.gov/pubmed/21112079
|
